McMillan Office’s AstraZeneca AZN Stock Holding History

McMillan Office’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$117K	Hold	616	–	–	0.01%	232
2026 Q1	$121K	Sell	616 -1	-0.2%	-$193	0.02%	218
2025 Q4	$113K	Buy	+617	New	+$108K	0.01%	227

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

McMillan Office's AZN Position: Q2 2026 in Review

McMillan Office held its AstraZeneca (AZN) position steady in Q2 2026 at 616 shares worth $117K. The position accounts for 0.01% of the portfolio, ranked #232.

McMillan Office first reported a position in AZN in Q4 2025 and has held it in 3 quarters since. The position peaked at $121K in Q1 2026. 1,495 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

McMillan Office held 616 shares of AstraZeneca worth $117K as of Q2 2026.
McMillan Office left its AstraZeneca share count unchanged in Q2 2026.
AstraZeneca made up 0.01% of McMillan Office's portfolio in Q2 2026, its #232 holding.
McMillan Office first reported a position in AstraZeneca in Q4 2025 and has held it in 3 quarters since.
McMillan Office's AstraZeneca position peaked at $121K in Q1 2026.
1,495 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on McMillan Office's 13F filing for Q2 2026, filed 13 Aug 2026.